Batoclimab Phase 3 for Generalized Myasthenia Gravis Reaches Primary Completion

A Phase 3 study evaluating batoclimab for adult participants with generalized myasthenia gravis (gMG) reached its primary completion on 2025-01-10. This trial, identified as NCT05403541, enrolled 240 participants to assess the drug's efficacy and safety.

Background

The study focuses on generalized myasthenia gravis (gMG), a chronic autoimmune neuromuscular disease characterized by weakness in the voluntary muscles. The trial aimed to confirm the efficacy and safety of batoclimab as both induction and maintenance therapy for this condition.

Trial design

The Phase 3 study (NCT05403541) enrolled 240 adult participants with generalized myasthenia gravis. The trial was designed as a 4-period study to confirm the efficacy and safety of batoclimab. Participants in Period 1 were randomized 1:1:1 to receive batoclimab 680 mg subcutaneously (SC) once a week (QW), batoclimab 340 mg SC QW, or matching placebo SC. The primary efficacy endpoint for the study was assessed by the change in the myasthenia gravis activities of daily living (MG-ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previously treated with batoclimab were re-randomized to continue on batoclimab (340 mg SC QW or 340 mg SC bi-weekly).

What this means

The primary completion of this Phase 3 study for batoclimab in generalized myasthenia gravis indicates that all participants have completed the predefined primary endpoint assessment period. This milestone signifies that the core data collection for the primary efficacy analysis has concluded. While this event marks a significant step forward in the clinical development of batoclimab, it does not yet provide specific efficacy or safety results. The next step will involve data analysis and subsequent reporting of the trial's findings, which will determine the potential of batoclimab as an induction and maintenance therapy for adult participants with gMG. Clinicians and patient advocates will await the detailed results to understand the full implications for patient care.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05403541, titled "Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis", was updated with a primary completion date of 2025-01-10 on clinicaltrials.gov.